Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN EBITDA Margin

EBITDA as a percentage of revenue.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

EBITDA Margin · Q4 FY2025 · quarter ended Dec 2025

EBITDA Margin widens to 59.1%

EBITDA Margin was 59.1% in Q4 FY2025, up 111.5 pp from a year earlier. Over 3 fiscal years it widened by 24.1 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
59.1%— QoQ
Last fiscal yearDec 2025
66.7%+35.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+111.5 pp——
1 year+35.3 pp——
3 years+24.1 pp——
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
66.7%
Year-over-year change
+35.3pp

EBITDA Margin vs competitors

How NNNN compares with its peers on the latest reported figures

  • NNNN's FY2025 EBITDA Margin of 66.7% is the highest of the 10 companies compared; the peer median is -1.7%.
  • Its year-over-year change of +35.3 pp is the 2nd highest of 9, against a peer median of +5.6 pp.
  • Over three fiscal years its change of +24.1 pp compares with a peer median of +19.4 pp.
NNNN Competitors Peer median
EBITDA Margin for NNNN and competitors
Company Period LTM level YoY 3-year change
NNNNAnbio Biotechnology Class A Ordinary SharesFY202566.7% +35.3 pp+24.1 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202643.8% +19.9 pp+89.5 pp
CYHCommunity Health Systems, Inc.LTM Mar 202623.1% +13.2 pp+6.6 pp
SNDLSNDL Inc.LTM Mar 20265.3% +10.5 pp+50.9 pp
TALKTalkspace, Inc.LTM Mar 20262.6% +0.4 pp+70.2 pp
ANGOAngioDynamics, Inc.LTM Feb 2026-1.7% -1.9 pp-2.9 pp
AVNSAvanos Medical, Inc.LTM Mar 2026-3.0% +46.3 pp-16.1 pp
CLPTClearPoint Neuro, Inc.LTM Mar 2026-58.2% +0.7 pp+19.4 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-101.1% ——
GOSSGossamer Bio, Inc.LTM Mar 2026-304.0% -275.3 pp—
CMPSCOMPASS Pathways plcFY2025— ——
Peer median (excluding NNNN) -1.7%+5.6 pp+19.4 pp

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.43M23.54M6.71M8.19M9.76M
Cost of Revenue1.89M10.98M3.35M2.3M1.25M
Gross Profit2.54M12.56M3.36M5.89M8.51M
Gross Margin57.4%53.4%50.1%71.9%87.2%
Research & Development0200K134.7K454.23K227.19K
Selling, General & Admin86.1K2.17M1.27M3.44M1.78M
Operating Expenses86.1K2.37M1.4M3.89M2M
Depreciation & Amortization06.25K13.04K00
EBITDA2.54M10.03M2.27M2.57M6.51M
EBITDA Margin57.3%42.6%33.8%31.4%66.7%
Operating Income2.46M10.2M1.96M2M6.51M
Operating Margin55.5%43.3%29.2%24.4%66.7%
Interest Income042.25K165.34K337.51K160.28K
Interest Expense08K000
Other Income / Expenses79.94K(184.41K)292.78K377.48K717.46K
Income Before Tax2.54M10.01M2.25M2.37M7.23M
Pre-Tax Margin57.3%42.5%33.6%29.0%74.1%
Income Tax Expense00000
Net Income2.54M10.01M2.25M2.37M7.23M
Net Margin57.3%42.5%33.6%29.0%74.1%
EPS (Basic)0.030.070.020.060.16
EPS (Diluted)0.030.070.010.060.16
Weighted Avg Shares100M143.89M143.89M42.29M43.89M
Weighted Avg Shares (Diluted)100M143.89M187.78M42.29M43.89M

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.